Matrigen Inc. was formed to develop and commercialize a cost-effective technology to combat disease process in bone and tissue and stimulate tissue regeneration. The company's products will be based on controlled-release technologies that will deliver DNA to the diseased area.
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.
Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.